Status and phase
Conditions
Treatments
About
To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Lung Cancer.
Eligibility:
Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.
Full description
A total of 40 patients may be enrolled over a period of 1-2 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Bi Wang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal